The EPO offers a number of mechanisms for expediting the grant procedure. As noted in the EPO’s November 2015 notice these include:
- PACE (see below for changes)
- Waiving the confirm to proceed notification under rule 70(2) EPC
- Waiving the rules 161/162 EPC communication
- Waiving a further communication under rule 71(3) EPC
- Early entry into the European phase
During post grant proceedings the above EPO Notice also highlights accelerated processing of oppositions where infringement proceedings have been instituted and accelerated processing before the Boards of Appeal.
From 1 January 2016, (Happy New Year everyone!), the EPO has tweaked the operation of the PACE programme slightly. Full details can be found in the EPO’s PACE Notice dated 30 November 2015. The highlights are as follows: (more…)
As we contemplate the possibility that another recipe from “101 Things to do with Cold Turkey” is going to be needed to shift the last of the Christmas food, we thought we’d take a quick look back at the top 10 most read posts that we published this year. (more…)
The US patent prosecution process can become a bit confusing once the application reaches the “final” Office Action stage. The “final” nature of the Office Action (OA) means that the Examiner has rejected the claims at least two times. However, it is by no means the end of the process with after-final amendments, appeal and a request for continued examination often being on the cards.
The various options available to the applicant were the subject of a recent webinar that IPcopy attended and what follows is a summary of the webinar (any errors clearly being the work of the author of this post!). (more…)
Christmas is nearly here and barring any end of the year UPC ratifications we’re not expecting too much to happen on the unitary patent and Unified Patent Court until next year. Before Christmas arrives however here’s a quick update: (more…)
A trade secret is a formula, practice, process, design, instrument, pattern, commercial method, or compilation of information which is not generally known or reasonably ascertainable by others, and by which a business can obtain an economic advantage over competitors or customers. The scope of trade secrets is virtually unlimited. (more…)
The European Commission website provides something of a byzantine navigational challenge so IPcopy is extremely grateful to Martin Chatel for pointing us in the direction of the Commission staff working document “A Single Market Strategy for Europe – Analysis and Evidence” which discusses the unitary patent package. (more…)
As previously reported on IPcopy, HM Treasury and HM Revenue and Customs are currently running a consultation on proposed changes to the UK Patent Box scheme. The consultation runs until this Friday (4 December 2015) and the consultation document, which includes some background on the existing Patent Box scheme, can be found here.
The main change proposed in the consultation is the use of R&D expenditure as a proxy for “substantial activities”. A so called “nexus fraction” will then be calculated in which a company’s own R&D expenditure on the IP in question plus any subcontracted R&D expenditure to an unrelated party (these figures together forming the “qualifying expenditure”) will be divided by the qualifying expenditure plus any R&D subcontracted to a related party plus acquisition costs.
Companies who have developed their own IP are likely to have a nexus fraction of close to “1” and so will essentially be unaffected by the revised rules. However, company’s which have acquired IP will see nexus fractions of <1 which will therefore reduce the income which qualifies for the new Patent Box.
Although the main change is the use of R&D expenditure as a proxy for substantial activities it is noted that the proposed changes will also have some other fairly noticeable effects, namely: (more…)
In today’s update we highlight an article relating to Supplementary Protection Certificates (SPCs) and the UPC and an article that discusses the interest of US applicants for unitary patent protection. We also have the most recent update from the UK’s UPC Taskforce. (more…)
What is an IP licence?
An IP licence in its simplest form is an agreement where an IP owner (the Licensor) permits another person (the Licensee) to engage in activities that, in the absence of the IP Licence Agreement, would infringe the Licensor’s legal rights attaching to the IP. In return the Licensee pays the Licensor a fee or confers some other benefit. It is a written agreement that gives rights to do something that would otherwise be an infringement of the IP rights of someone else.
A typical case may involve the Licensor granting the Licensee the right to make and sell patented product perhaps worldwide and for the life of the patent(s). The Licensee agrees to pay the Licensor a royalty, defined as a percentage of Net Sales Value. The Licensor agrees not to make or sell patented product itself nor permit any 3rd Party to do so. (more…)